Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Psoriasis Stories

2012-11-15 08:31:01

LA JOLLA, Calif., Nov. 15, 2012 /PRNewswire/ -- Auspex Pharmaceuticals, Inc. today announced that it has been granted U.S. Patent No. 8,299,084 covering the company's novel JAK kinase inhibitor SD-900, a deuterium-substituted analogue of tofacitinib. "The issuance of a composition-of-matter patent for SD-900 is strong validation of Auspex's technological approach to the creation of important new drugs," said Lawrence C. Fritz, Ph.D., President and Chief Executive Officer of Auspex....

2012-11-12 08:28:21

ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott today announced results from a post-hoc analysis of HUMIRA(®) (adalimumab) data in early and long-standing moderate-to-severe rheumatoid arthritis (RA) patients from three randomized, controlled trials--DE019, OPTIMA and PREMIER. The analysis evaluated the simultaneous achievement of three key treatment goals: low disease activity, normal physical function and the absence of radiographic progression at one year. These results are...

2012-11-12 08:27:42

WASHINGTON, Nov. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today new findings from PSUMMIT II, a Phase 3 investigational study that showed patients with active psoriatic arthritis, including those previously treated with one to five tumor necrosis factor (TNF) inhibitors, receiving the interleukin (IL)-12/23 inhibitor STELARA(®) (ustekinumab) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patients...

2012-11-12 04:23:38

TRONDHEIM, Norway, November 12, 2012 /PRNewswire/ -- Avexxin AS, a company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the closure of a financing B round with new and existing shareholders. Avexxin's lead project against psoriasis is expected to enter clinical trial phase I/IIa early 2013. The company also has pre-clinical development programs against rheumatoid arthritis and...

2012-11-05 04:21:51

CANTERBURY, England, November 5, 2012 /PRNewswire/ -- GBP1.42m Funding Will Drive Development of New Treatment for Atopic Dermatitis Creabilis SA, a European biotechnology company specialising in the development of treatments in dermatology, inflammation and pain, today announces that it has been granted a prestigious Biomedical Catalyst funding award of GBP1.42m. Creabilis is one of the first companies to receive this...

2012-11-02 07:27:32

NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. The presentation will highlight new, pivotal Phase 3 study findings, including; Intravenous Golimumab Inhibits Radiographic Progression and...

2012-10-29 15:26:01

JACKSON, Wis., Oct. 29, 2012 /PRNewswire/ --Lake Consumer Products, owner and manufacturer of the MG217® line of psoriasis treatment products, recently introduced an innovative new multi-symptom psoriasis treatment cream that's revolutionary in the psoriasis treatment category because it's fragrance-free, fast-absorbing and non-staining to skin and clothing. (Photo: http://photos.prnewswire.com/prnh/20121029/CG01996) "We really listened to our customers while developing this product,"...

2012-10-29 11:25:58

Be Joint Smart educates public about devastating disease affecting 87,000 Ohioans CLEVELAND, Oct. 29, 2012 /PRNewswire-USNewswire/ -- For the first-time ever, the National Psoriasis Foundation and the Arthritis Foundation will partner to educate Americans about psoriatic arthritis, a chronic autoimmune disease that affects roughly 87,000 Ohioans. To emphasize the importance of early diagnosis and treatment, the Psoriasis Foundation and Arthritis Foundation present the first psoriatic...

2012-10-29 11:25:32

AUSTIN, Texas, Oct. 29, 2012 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human monoclonal antibody (MABp1) in patients with type 2 diabetes. Results from this study continue to reinforce the role of IL-1a as a master regulator of chronic inflammation in multiple disease states, and the therapeutic benefits of neutralizing antibodies produced from the XBiotech platform. The Company...

2012-10-29 03:20:51

BEERSE, Belgium, October 29, 2012 /PRNewswire/ -- Pledge Your Support Today to Help Drive Much-needed Change for People With Psoriasis Promising interim results from the Psoriasis Mandate have been released today to mark World Psoriasis Day [http://www.worldpsoriasisday.com ]. To date 1145 people across 40 European countries have pledged their support for five basic rights of people with psoriasis, but experts are urging...